{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007596","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.655609+00:00","generated_at":"2026-06-02T05:01:07.868124+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium Q1 net revenue $144.9M, GAAP net income $27.7M, CEO steps down May 24","bullets":["GAAP net income of $27.7M ($0.71 diluted EPS) vs. loss of $(17.4M) in Q1 2023.","Adjusted EBITDA of $92.4M, up 5% YoY; non-GAAP adjusted EPS of $1.45.","Record Belbuca revenue of $50.7M, up 15% YoY; total prescriptions up 4.2%.","CEO Joe Ciaffoni to step down May 24, 2024; Michael Heffernan named interim CEO.","Board authorized $35M accelerated share repurchase program; reiterated FY2024 guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007596","json":"https://secwatch.observer/filing/0001558370-24-007596.json","markdown":"https://secwatch.observer/filing/0001558370-24-007596.md","text":"https://secwatch.observer/filing/0001558370-24-007596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/0001558370-24-007596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/coll-20240509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:01:07.868124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ebc2e215a3343d1ffe7bf859b439895362490584","claim":"COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2024 results: revenue $144.9 million, net income $27.7 million, EPS $0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted). Guidance reaffirmed.","evidence_excerpt":"under Item 2.02 of this Current Report on Form 8-K. ​ --- EX-99.1 (EX-99.1) --- ​ Collegium Reports First Quarter 2024 Financial Results ​ – Generated Q1’24 Net Revenue of $144.9 Million – ​ – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – ​ – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837024007596/0001558370-24-007596-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$144.9 million"},{"label":"Net income","value":"$27.7 million"},{"label":"EPS","value":"$0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}